Extraction optimization and in vitro and in vivo anti-postprandial hyperglycemia effects of inhibitor from Phoenix dactylifera L. parthenocarpic fruit - 13/03/17
, Mouna Chakroun a, Imen Fendri b, Mohamed Makni b, Mohamed Bouaziz c, Noureddine Drira a, Hafedh Mejdoub a, Bassem Khemakhem a| pages | 9 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | Extraction optimization of glycosyl hydrolase inhibitors from Sish. |
• | LC–MS/MS analysis showed the presence of 13 phenolic compounds. |
• | The aqueous ethanolic extract was effective in inhibiting amylase and glucosidase. |
• | The aqueous ethanolic extract could be used as an anti-hyperglycemic agent. |
Abstract |
Phoenix dactylifera L. plays an important role in social, economic, and ecological Tunisian sectors. Some date palms produce parthenocarpic fruit named Sish. The aqueous ethanolic extract from P. dactylifera parthenocarpic dates demonstrated a potent inhibition of the enzymes related to type II diabetes. In this work, extraction optimization of amylase inhibitors was carried out using Box-Behnken Design. Bioactivity-guided fractionation of the 70% aqueous ethanol extract was performed to identify the active compounds. The physicochemical results by liquid chromatography-tandem mass spectrometry (LC–MS/MS) analysis showed the presence of 13 phenolic compounds. The in vitro study showed that the extract exhibited a more specific inhibitor of α-glucosidase than α-amylase with an IC 50 value of 0.6 and 2.5 mg/mL, respectively. The in vivo study of this extract effect on the postprandial hyperglycemia activity showed a decrease in plasma glucose levels after 30 min stronger than the Acarbose effect. These results confirmed the anti-postprandial hyperglycemia activity of the aqueous ethanolic extract from P. dactylifera parthenocarpic dates, which could lend support for its pharmaceutical use.
Le texte complet de cet article est disponible en PDF.Keywords : Parthenocarpic dates, Box-Behnken design, LC–MS/MS analysis, Glucosyl hydrolase, Inhibitor, Hyperglycemia
Plan
Vol 88
P. 835-843 - avril 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?
